chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Fatigue, Pain
Clinical narrative: experienced pain in her joints, muscles; she was feeling very tired; she is feeling sick in her stomach; experienced pain in her joints, muscles; This is a spontaneous report from a contactable consumer (patient) via Pfizer-sponsored program. A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 20Feb2021 as DOSE 2, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient received first dose of BNT162B2 for covid-19 immunisation. On Feb2021, the patient experienced pain in her joints, muscles, and she was feeling very tired. The patient also reported that she was feeling sick in her stomach. The outcome of the events was unknown.   No follow-up attempts are possible; information about batch/ lot number cannot be obtained.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal discomfort, Arthralgia, Fatigue, Myalgia
Clinical narrative: experienced pain in her joints, muscles; she was feeling very tired; she is feeling sick in her stomach; experienced pain in her joints, muscles; This is a spontaneous report from a contactable consumer (patient) via Pfizer-sponsored program. A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 20Feb2021 as DOSE 2, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient received first dose of BNT162B2 for covid-19 immunisation. On Feb2021, the patient experienced pain in her joints, muscles, and she was feeling very tired. The patient also reported that she was feeling sick in her stomach. The outcome of the events was unknown.   No follow-up attempts are possible; information about batch/ lot number cannot be obtained.
Age: 64.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: Rash on legs, Still have rash 101 hours after vaccination. Raised rash on inner thighs, knee caps and shins.; This is a spontaneous report from a contactable consumer (patient). A 64-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection) via an unspecified route of administration at arm left (at the age of 64-year-old) on 20Feb2021 10:30 (Batch/Lot number was not reported) as single dose for COVID-19 immunization. Medical history included pre-diabetic and high cholesterol. Concomitant medications included rosuvastatin and metformin. The patient experienced rash on legs, Still have rash 101 hours after vaccination. Raised rash on inner thighs, knee caps and shins on 20Feb2021 16:00. The patient did not receive treatment for event.   Follow-up attempts completed. No further information expected; Information on lot/batch number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Condition aggravated, Influenza A virus test negative, Influenza B virus test, Respiratory syncytial virus test negative
Clinical narrative: After receiving the vaccine I developed swollen lymph gland near my collar bone.  I noticed the lump on April 21,2021.; This is a spontaneous report from a contactable other health care professional. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Ew 0164) via an unspecified route of administration in the left  arm on 19Apr2021 at 19:15 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) both for unknown indication on unknown date and unknown if ongoing. On 21Apr2021 at 08:00, after receiving the vaccine, the patient developed swollen lymph gland near her collar bone and noticed the lump. No therapeutic measures were taken as a result of the reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph gland near collar bone was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: After receiving the vaccine I developed swollen lymph gland near my collar bone.  I noticed the lump on April 21,2021.; This is a spontaneous report from a contactable other health care professional. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Ew 0164) via an unspecified route of administration in the left  arm on 19Apr2021 at 19:15 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) both for unknown indication on unknown date and unknown if ongoing. On 21Apr2021 at 08:00, after receiving the vaccine, the patient developed swollen lymph gland near her collar bone and noticed the lump. No therapeutic measures were taken as a result of the reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph gland near collar bone was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy
Clinical narrative: After receiving the vaccine I developed swollen lymph gland near my collar bone.  I noticed the lump on April 21,2021.; This is a spontaneous report from a contactable other health care professional. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: Ew 0164) via an unspecified route of administration in the left  arm on 19Apr2021 at 19:15 (at the age of 57-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) both for unknown indication on unknown date and unknown if ongoing. On 21Apr2021 at 08:00, after receiving the vaccine, the patient developed swollen lymph gland near her collar bone and noticed the lump. No therapeutic measures were taken as a result of the reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph gland near collar bone was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Neuropathy peripheral, Paraesthesia
Clinical narrative: Paresthesia starting in  legs 8 hours post vaccine, it has spread to  feet, hands, arms, face.; Muscle aches and weakness in legs. Very mild exercise leaves muscles with a dull ache for 8 hours. Legs felt like jelly; Muscle aches and weakness in legs. Very mild exercise leaves muscles with a dull ache for 8 hours. Legs felt like jelly; This is a spontaneous report from a contactable other healthcare professional (patient).   A 36-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Batch/Lot Number: unknown) via an unspecified route of administration in the arm left on 26May2021 at 18:00 (at the age of 36 years old) as dose 1, single dose for COVID-19 immunisation. Medical history included thalassemia minor, minor mitral valve regurgitation and seborrheic dermatitis.  Concomitant medications included vitamins. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27May2021 at 02:00 8 hours post vaccine, the patient experienced paresthesia starting in legs, it was spread to feet, hands, arms and face. The patient also had muscle aches and weakness in legs. It was reported that very mild exercise leaved muscles with a dull ache for 8 hours and the legs felt like jelly. The symptoms were not subsided after 8 days. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events muscle aches and weakness in legs, very mild exercise leaves muscles with a dull ache, legs felt like jelly and paresthesia starting in legs, spread to feet, hands, arms, face was not recovered at the time of this report.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.  The lot number for BNT162B2, was not provided and will be requested during follow up.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Muscular weakness, Myalgia, Paraesthesia
Clinical narrative: Paresthesia starting in  legs 8 hours post vaccine, it has spread to  feet, hands, arms, face.; Muscle aches and weakness in legs. Very mild exercise leaves muscles with a dull ache for 8 hours. Legs felt like jelly; Muscle aches and weakness in legs. Very mild exercise leaves muscles with a dull ache for 8 hours. Legs felt like jelly; This is a spontaneous report from a contactable other healthcare professional (patient).   A 36-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Batch/Lot Number: unknown) via an unspecified route of administration in the arm left on 26May2021 at 18:00 (at the age of 36 years old) as dose 1, single dose for COVID-19 immunisation. Medical history included thalassemia minor, minor mitral valve regurgitation and seborrheic dermatitis.  Concomitant medications included vitamins. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27May2021 at 02:00 8 hours post vaccine, the patient experienced paresthesia starting in legs, it was spread to feet, hands, arms and face. The patient also had muscle aches and weakness in legs. It was reported that very mild exercise leaved muscles with a dull ache for 8 hours and the legs felt like jelly. The symptoms were not subsided after 8 days. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events muscle aches and weakness in legs, very mild exercise leaves muscles with a dull ache, legs felt like jelly and paresthesia starting in legs, spread to feet, hands, arms, face was not recovered at the time of this report.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.  The lot number for BNT162B2, was not provided and will be requested during follow up.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heavy menstrual bleeding
Clinical narrative: Menstrual bleeding since second dose. Its been more than a month now. And its heavy; This is a spontaneous report from a contactable consumer (patient). A 31-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) via an unspecified route of administration on 26Apr2021 (Batch/Lot number was not reported) as dose 2, single for COVID-19 immunisation. Medical history included none (reported other medical history: no). The patient has no known allergies. The patient was not pregnant at the time of the event. The patient's concomitant medications were not reported. The patient did not receive other vaccine in four weeks. The patient did not receive other medications in two weeks. The patient did not have COVID prior to vaccination and had not been test for COVID post-vaccination. On 27Apr2021, the patient experienced menstrual bleeding since second dose. According to the patient, it has been more than a month and was heavy. The event resulted in emergency room/department/urgent care visit. Progesterone was received as a treatment for the event. The outcome of the event was not recovered/not resolved.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Electrocardiogram, Palpitations, Sinus rhythm, Urticaria
Clinical narrative: Event: widespread hives and rash, severe itching, numbness of lips Treatment: cortisone shot, cortisone pills, anti-itch pills Outcome: itching subsided after several hours, rash and hives diminished after a several hours but persisted for a second day
Age: 62.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Hypoaesthesia oral, Pruritus, Rash, Urticaria
Clinical narrative: Event: widespread hives and rash, severe itching, numbness of lips Treatment: cortisone shot, cortisone pills, anti-itch pills Outcome: itching subsided after several hours, rash and hives diminished after a several hours but persisted for a second day
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chest X-ray, Chest pain, Dyspnoea, Electrocardiogram, Full blood count
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, International normalised ratio, Metabolic function test, Prothrombin time
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Abdominal pain, Abdominal pain upper, Biliary obstruction, Blood culture, Blood lactic acid
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood magnesium, C-reactive protein, Computerised tomogram abdomen, Culture urine, Differential white blood cell count
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Electrocardiogram, Full blood count, Haematemesis, Hypokalaemia, Inflammation
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Influenza A virus test, Influenza B virus test, Lipase increased, Liver function test abnormal, Metabolic function test
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nausea, Occult blood, Respiratory syncytial virus test, SARS-CoV-2 test, Scan with contrast
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Secondary hypertension, Urine analysis, Vomiting
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Abdominal X-ray, Bile duct stone, Breast mass, Cholecystectomy, Computerised tomogram abdomen
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Differential white blood cell count, Dilatation intrahepatic duct acquired, Endoscopic retrograde cholangiopancreatography, Full blood count, International normalised ratio
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Metabolic function test, Peripheral artery occlusion
Clinical narrative: Lump in right breast  She was notified that with these findings it would necessitate urgent endoscopic evaluation with ERCP to relieve the obstruction along with IV antibiotic therapy to minimize the potential for ascending cholangitis She was instructed to go to the emergency room for initiation of IV fluids, laboratory studies including LFTs, as well as IV antibiotics such as Zosyn as well as to initiate transfer to other medical facility for choledocholithiasis and for GI consultation for ERCP  1. Two new 9 mm rounded lesions within the common bile duct, likely representing choledocholithiasis. Associated increased dilatation of the extrahepatic duct and new intrahepatic duct dilatation. Recommend GI consultation with consideration for ERCP.  2. Occlusion of the upper right superficial femoral artery, new since the prior CT.  Cholecystectomy. Since prior CT 2/12/2019, development of intrahepatic duct dilatation and increased dilatation of the extrahepatic duct now measuring up to 21 mm in diameter (previously 17 mm). Two new rounded lesions within the common bile duct each measuring approximately 9 mm. One is in the mid common bile duct and the other is in the distal duct (coronal series 300, images 47-48). These likely represent choledocholithiasis, less likely soft tissue lesions.
Age: 28.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Discomfort, Feeling hot, Pain, Paraesthesia
Clinical narrative: Experienced the pain shooting on both of the legs; This is a spontaneous report from a contactable pharmacist. A 28-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EY0584; Expiration Date: Oct2021), via an unspecified route of administration on 27Jul2021 (at the age of 28-year-old) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date in Jul2021, patient experienced the pain shooting on both of the legs and it lasted about an hour or so and then it did not happen again until 11 o clock this morning and it happened and it lasted for two or three hours (at the time of report). Outcome of the event was unknown.
Age: 28.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity
Clinical narrative: Experienced the pain shooting on both of the legs; This is a spontaneous report from a contactable pharmacist. A 28-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EY0584; Expiration Date: Oct2021), via an unspecified route of administration on 27Jul2021 (at the age of 28-year-old) as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date in Jul2021, patient experienced the pain shooting on both of the legs and it lasted about an hour or so and then it did not happen again until 11 o clock this morning and it happened and it lasted for two or three hours (at the time of report). Outcome of the event was unknown.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Biopsy skin, Rash, Skin burning sensation, Skin reaction, Urticaria
Clinical narrative: patient had bright burning rash, urticarial rash and focal neuropathy
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Burning sensation, Neuropathy peripheral, Rash, Urticaria
Clinical narrative: patient had bright burning rash, urticarial rash and focal neuropathy
Age: 23.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Hypoaesthesia
Clinical narrative: Blackouts; Hot flashes; Uncontrollable sweating; Fatigue; Dizziness/ Lightheadedness; Tingling/ Numbing in both arms; Tingling/ Numbing in both arms; This is a spontaneous report received from a contactable consumer. This 23-year-old male consumer (patient) reported for himself that who received bnt162b2 (BNT162B2, solution for injection, lot number FC3182), dose 1 via an unspecified route of administration in left arm on 17Aug2021 15:45 (at the age of 23-years-old) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Aug2021 15:46 the patient experienced blackouts, hot flashes, uncontrollable sweating, fatigue, dizziness/light-headedness, tingling/numbing in both arms. Symptoms occurred roughly one minute after vaccination and lasted roughly 12 minutes.  No treatment was given for adverse event. Outcome of the events was recovered on an 17Aug2021.  Follow-up attempts are completed. No further information is expected.
Age: 23.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Fatigue, Hot flush, Hyperhidrosis, Hypoaesthesia
Clinical narrative: Blackouts; Hot flashes; Uncontrollable sweating; Fatigue; Dizziness/ Lightheadedness; Tingling/ Numbing in both arms; Tingling/ Numbing in both arms; This is a spontaneous report received from a contactable consumer. This 23-year-old male consumer (patient) reported for himself that who received bnt162b2 (BNT162B2, solution for injection, lot number FC3182), dose 1 via an unspecified route of administration in left arm on 17Aug2021 15:45 (at the age of 23-years-old) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Aug2021 15:46 the patient experienced blackouts, hot flashes, uncontrollable sweating, fatigue, dizziness/light-headedness, tingling/numbing in both arms. Symptoms occurred roughly one minute after vaccination and lasted roughly 12 minutes.  No treatment was given for adverse event. Outcome of the events was recovered on an 17Aug2021.  Follow-up attempts are completed. No further information is expected.
Age: 23.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Loss of consciousness, Paraesthesia
Clinical narrative: Blackouts; Hot flashes; Uncontrollable sweating; Fatigue; Dizziness/ Lightheadedness; Tingling/ Numbing in both arms; Tingling/ Numbing in both arms; This is a spontaneous report received from a contactable consumer. This 23-year-old male consumer (patient) reported for himself that who received bnt162b2 (BNT162B2, solution for injection, lot number FC3182), dose 1 via an unspecified route of administration in left arm on 17Aug2021 15:45 (at the age of 23-years-old) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Aug2021 15:46 the patient experienced blackouts, hot flashes, uncontrollable sweating, fatigue, dizziness/light-headedness, tingling/numbing in both arms. Symptoms occurred roughly one minute after vaccination and lasted roughly 12 minutes.  No treatment was given for adverse event. Outcome of the events was recovered on an 17Aug2021.  Follow-up attempts are completed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest discomfort, Dyspnoea, Pruritus, Stomatitis, Urticaria
Clinical narrative: then breathing problems through the night; felt like a weight on my chest and itching all over; hives; felt like a weight on my chest and itching all over; This is a spontaneous report from a contactable consumer (patient). A 51-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in Arm Right on 11Aug2021 15:00 (Batch/Lot Number: FC3180) (at the age of 51 years) as DOSE 1, SINGLE for covid-19 immunisation. Medical history was none. Patient previously took Demerol (also reported as demeral), zpak (as reported, also included tree nuts, msg, fake sugar, red dye, pennic). Concomitant medications included propranolol hydrochloride (PROPRANOL) taken for an unspecified indication, start and stop date were not reported; montelukast sodium (SINGULAIR) taken for an unspecified indication, start and stop date were not reported; fluticasone propionate (FLONASE [FLUTICASONE PROPIONATE]) taken for an unspecified indication, start and stop date were not reported; fish oil (FISH OIL) taken for an unspecified indication, start and stop date were not reported; vitamin d3 (VITAMIN D3) taken for an unspecified indication, start and stop date were not reported; cyanocobalamin (VITAMIN B12 [CYANOCOBALAMIN]) taken for an unspecified indication, start and stop date were not reported. The patient experienced hives all over, felt like a weight on chest and itching all over, then breathing problems through the night all on 11Aug2021 19:00 with outcome of recovering. Therapeutic measures were taken as a result of events. Patient called physician and said to take Benadryl and allergy medications. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest discomfort, Dyspnoea, Pruritus, Urticaria
Clinical narrative: then breathing problems through the night; felt like a weight on my chest and itching all over; hives; felt like a weight on my chest and itching all over; This is a spontaneous report from a contactable consumer (patient). A 51-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in Arm Right on 11Aug2021 15:00 (Batch/Lot Number: FC3180) (at the age of 51 years) as DOSE 1, SINGLE for covid-19 immunisation. Medical history was none. Patient previously took Demerol (also reported as demeral), zpak (as reported, also included tree nuts, msg, fake sugar, red dye, pennic). Concomitant medications included propranolol hydrochloride (PROPRANOL) taken for an unspecified indication, start and stop date were not reported; montelukast sodium (SINGULAIR) taken for an unspecified indication, start and stop date were not reported; fluticasone propionate (FLONASE [FLUTICASONE PROPIONATE]) taken for an unspecified indication, start and stop date were not reported; fish oil (FISH OIL) taken for an unspecified indication, start and stop date were not reported; vitamin d3 (VITAMIN D3) taken for an unspecified indication, start and stop date were not reported; cyanocobalamin (VITAMIN B12 [CYANOCOBALAMIN]) taken for an unspecified indication, start and stop date were not reported. The patient experienced hives all over, felt like a weight on chest and itching all over, then breathing problems through the night all on 11Aug2021 19:00 with outcome of recovering. Therapeutic measures were taken as a result of events. Patient called physician and said to take Benadryl and allergy medications. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.
Age: 38.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Migraine
Clinical narrative: Within 5 minutes of first shot given a migraine began. Every day since I battle the same migraine.; This is a spontaneous report from a contactable consumer or other non hcp.    A 38-year-old female (non-pregnant) patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot no: EW0176), via an unspecified route of administration on 05May2021 13:15 (at the age of 38-year-old) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included PCOS (polycystic ovaries), endometriosis, adenomyosis, fibrocystic breast disease, Heart attack, stroke, allergies from Apples, Bananas, kiwi (Food allergy) ( known allergies: Apples, Bananas, kiwi) , allergies: Penicillin (drug hypersensitivity) (known allergies: Penicillin), rubber sensitivity (known allergies: Latex ), dermatitis contact (known allergies: adhesive), the patient previously took niacin and experienced drug hypersensitivity (known allergies: Niacin) all from an unknown date and unknown if ongoing. The patient had allergies from all antibiotics (Drug hyper-sensitivity) from an unknown date and unknown if ongoing (known allergies: all antibiotics). Concomitant medications included Crestor (rosuvastatin calcium); Allegra D (fexofenadine hydrochloride, pseudoephedrine hydrochloride); vitamin C (ascorbic acid); Motrin (IBUPROFEN); and Elder-berry (sambucus nigra). It was reported that no other vaccine administered in four weeks. It was reported that patient was not diagnose with covid prior to vaccination. covid tested post vaccination was no. Within 5 minutes of first shot given, the patient experienced a migraine began, it was stated that every day since she battle the same migraine on 05May2021 13:30. Adverse event resulted in Disability or permanent damage. No therapeutic measure were taken as a result of event. The outcome of event was reported as not recovered.
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood test, Computerised tomogram, Echocardiogram, Magnetic resonance imaging, Pulmonary embolism
Clinical narrative: I got blood clots in my lungs, both lungs about a month later; I got blood clots in my lungs, both lungs about a month later; she had a pulmonary emboli; This is a spontaneous report from a contactable consumer (patient herself). A female patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: EW0151, expiry date: unknown) via unspecified route of administration in right arm on 20Apr2021 as dose 2, single for Covid-19 immunisation. Historical vaccine included first dose of BNT162B2 (Lot: ER8730) via unspecified route of administration in right arm, on 28Mar2021, as dose 1, single for Covid-19 immunisation. Patients medical history and concomitant medications were not reported. Patient stated that she got the vaccine, the Pfizer vaccine in April and got both the shots and got blood clots in her lungs less in a month and a half, both lungs about a month later, on an un-specified date in Jun2021. She ended up into an emergency room and was in the hospital for 4 days since 16Jul2021 and was on blood thinners, now and they can't find any other reason for the blood clot. She also had a pulmonary emboli, several of them actually on an unspecified date in 2021. She noticed symptoms starting 24Jun2021 but it probably started before then. The caller stated she still had the blood clots. They just give a person medication for 6 months and hope they go away. She remarked this was likely to continue, she would probably continue to get them based on how blood clots work. She doesn't know why she was even allowed to get the shots. She wanted to report the event. She could not find any data on blood clot except for the 'TTS' (not clarified) and saw that the only list confirmed cases. So, she wanted to know how was the case confirmed to be caused by the vaccine? She went to the doctor on 12Jul2021 and then had a CT scan done on 13Jul2021 and then was sent straight to emergency room but the symptoms started in June. She got Lovenox in the hospital for three days. Caller explains she was in the hospital from 13Jul2021-16Jul2021. She was put on Eliquis as treatment after leaving the hospital. She wanted them to know that several of her friends and people she has heard about who have got the shot from different manufacturers who have gotten blood clots. They have had no history or cause that was known. It was alarming that none of this was talked about and seem to be discouraged to talk about it. She hoped she saved someone's life. The patient underwent lab test for CT scan on 13Jul2021, with unknown results. The outcome of events for "I got blood clots in my lungs, both lungs about a month later" was not recovered and rest was unknown.   Follow-up attempts are completed. No further information is expected.